Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Sarcoma × sapanisertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma 1 Recurrence 1 Neurofibrosarcoma 1 Lymphoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Gliosarcoma 1 Glioblastoma 1 Dermatofibrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Advanced Nonhematological Neoplasms 1

Interventions

Doxorubicin 13 Gemcitabine 10 Cyclophosphamide 10 pazopanib 8 Filgrastim 8 Radiotherapy 7 Ifosfamide 7 Cisplatin 7 Irinotecan 6 Docetaxel 6 Radiation 5 Granulocyte Colony-Stimulating Factor 5 Etoposide 5 Trabectedin 4 Magnetic Resonance Spectroscopy 4 Celecoxib 4 Busulfan 4 Albumin-Bound Paclitaxel 4 sargramostim 3 pembrolizumab 3 X-Rays 3 Radiotherapy, Intensity-Modulated 3 Paclitaxel 3 Neoadjuvant Therapy 3 Leucovorin 3 Dexrazoxane 3 Cryosurgery 3 Blotting, Western 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡